Proceedings · Session S-323 · filed November 16, 2026
Research Funding & PolicySession paper
EU Pharmaceutical Overhaul Lands With Procurement Reform and 2028 Deadline
EU political agreement on November 10, 2026 replaces four cornerstone medicines laws, mandates national alignment by 2028, and reshapes procurement and trial advice.
By Tom Whitfield4 min read789 words
Summary
- European Parliament and Council reached political agreement on new pharmaceutical legislation on November 10, 2026, replacing four cornerstone EU medicines laws
- The EC adopted a Public Procurement Act proposal on September 8, 2026, allowing European preference criteria and Best Price-Quality Ratio as default award method
- The EMA's ACT EU clinical trial advice pilot, launched 2024, becomes permanent in January 2027, with lessons from ~30 applications due by year-end
- Revised GVP Module III took effect September 10, 2026, extending pharmacovigilance inspections across the full contracting chain
- EudraVigilance held 18.5 million individual cases as of August 2026, processing roughly 7,400 ICSR transactions per day in 2025
![<![CDATA[New Proposals and Legislation Strengthen Europe’s Position in the Pharmaceutical Arena]]>](/media/31/31b9cb0210ab5297.1280.webp)
On November 10, 2026, the European Parliament and the Council sealed a political agreement on the most sweeping reform of EU pharmaceutical law in two decades — a framework that will replace four cornerstone statutes and force every Member State to rewrite national rules by 2028.
The new pharmaceutical legislation (NPL) supersedes Regulation (EC) No 726/2004, the Orphan Medicines Regulation (EC) No 141/2000, elements of the Paediatric Medicines Regulation, and Directive 2001/83/EC. Its stated targets: industry competitiveness, unmet medical need, medicine shortages, and antimicrobial resistance (AMR). It also introduces fresh R&D incentives, including a transferable data exclusivity voucher (TDVE) for priority antimicrobials.
For R&D managers, the operational clock starts now. A two-year transition runs through 2028, backed by a dedicated governance structure. The European Medicines Agency (EMA) already ran a hybrid SME Info Day in November 2026 with case studies on how the changes affect development and authorization, plus a stakeholder meeting on priority-antimicrobial eligibility and TDVE transfer conditions. Implementation guidance from the European Commission (EC), EMA, and Member States will roll out over the coming months.
What changes in public procurement?
Two months before the legislative agreement, on September 8, 2026, the EC adopted a proposal for a Public Procurement Act. It would collapse the EU's current horizontal rules into a single, directly applicable regulation, push digitalization, and — notably — allow European preference criteria in strategic sectors.
The award methodology would shift toward the Best Price-Quality Ratio as the default, letting public buyers weigh environmental, social, innovation, security, and resilience factors. The European Federation of Pharmaceutical Industries and Associations (EFPIA) welcomed the proposal's focus on quality, innovation, resilience, security of supply, and sustainability, saying procurement should recognize pharmaceutical innovation rather than chase the lowest purchase price. EFPIA's caveat: price-only procurement should survive only in clearly defined exceptional circumstances.
For portfolio planning, that means award decisions in tenders would increasingly reward innovation and supply security — a shift vendors will price into European market strategies.
How does the trial advice pilot affect sponsors?
In October 2026, the EMA announced its ACT EU advice pilot, launched in 2024, becomes permanent in January 2027. Coordinated by the Heads of Medicines Agencies through its Clinical Trials Coordination Group, the procedure gives sponsors consolidated technical and regulatory feedback from concerned Member States before they file through the Clinical Trials Information System (CTIS).
Before the pilot, sponsors could get pre-submission support only from the single Member State evaluating their application. Now it's network-wide. ACT EU will manage applications already submitted through 2026, and a lessons-learned report covering roughly 30 applications lands by year-end. Updated sponsor guidance and templates go live on the CTCG website in January 2027. The EMA frames the move as support for the European Biotech Act.
What must clinical data teams do?
An EMA notice published October 29, 2026 sharpens accountability for computerized systems in clinical trials. Sponsors own validation, even when a vendor built and runs the system. Inspectors must be able to review validation documents regardless of who performed the work. If a vendor refuses audits, inspections, or access to specifications, the system should not be used. Time on the market counts for nothing. Fail to demonstrate validation, and regulators may reject the data outright.
That's a direct budget item: vendor audit clauses and validation documentation need review before the next system rollout.
What's new in pharmacovigilance?
Revised GVP Module III on pharmacovigilance inspections took legal effect September 10, 2026. It adds subcontracting provisions, removes clinical trial content governed elsewhere, refreshes fees and references, clarifies remote inspections, and strengthens the risk-based inspection cycle — confirming that inspections reach across the entire contracting chain and, for activities outside the EU, across borders.
Work continues on Modules II, IV, V, VI, and XV plus a vaccine-specific chapter, with a Module VII addendum on risk-minimization reporting planned and a broader Module VII revision starting in 2028 under the NPL. Consultations will be staggered over the year ahead.
From November 9, 2026, new qualified persons for pharmacovigilance and EudraVigilance responsible-person users must pass a 5-day online course and knowledge test before production access. The scale justifies the rigor: as of August 2026, EudraVigilance held 18.5 million individual cases, representing more than 32 million case transactions, and handled approximately 7,400 ICSR transactions per day in 2025. An HMA/EMA multi-stakeholder forum on EudraVigilance and signal detection follows on December 1, 2026, covering international guidance, signal management, and real-world evidence.
The Commission expects the NPL to deliver the clarity and predictability needed to sustain investment in European pharma R&D — with EMA guidance continuing to evolve throughout the year ahead.
via pharmtech.com (Source)
Filed under
- eu-pharmaceutical-policy
- european-medicines-agency
- clinical-trials
- public-procurement
- pharmacovigilance
More from Tom Whitfield
Show full bio
Senior reporter covering technology and product news in research and development at Hypothesis Wire.
268 articles
References
- FDA AI Warning Letter Raises the Bar for Model Validation
- FDA approval and four licensing deals anchor PharmTech roundup
- Medicines Patent Pool Signs 11 Firms for Generic Roche Flu Drug
- AI Playbook Expected December as Pharma Weighs Vendor Model Change Accountability
- Trump's 100% Pharma Tariff Takes Effect; Big Firms Defer Until 2029